Awarded by CIRM (California Institute for Regenerative Medicine), a"$8.5 million grant will be used to test gene-modified hematopoietic (or blood-forming) stem cells in patients and then monitor and analyze their effectiveness on the human immunodeficiency virus (HIV). " (#10)

"ViiV Healthcare is a global specialist HIV company dedicated to delivering advances in treatment and care for people living with HIV. Our current portfolio of twelve HIV treatments generated annual sales of £1.5 billion in 2014 providing us with the financial stability to take a sustainable, long-term view when investing in our pipeline of new medicines. Our scientists are 100% dedicated to finding new ways to limit the impact of HIV on the 35 million people living with the virus" (#8).

"The Harvard University Center for AIDS Research (HU CFAR) provides research, education and training opportunities to HU CFAR members across Harvard University and its affiliates through services that are in direct response to member needs. Areas of study by NIH-funded HU CFAR investigators include molecular virology, pathogenesis, host immune responses, epidemiology, treatment, vaccines and prevention" (#12).

"NIAID is committed to the research necessary to successfully end HIV/AIDS. Each year, 50,000 people in the United States become infected with HIV, the virus that causes AIDS. Currently, there are an estimated 1.1 million people in the United States and 34 million people globally who are living with HIV infection. In 2011, 1.7 million people died from AIDS-related causes. Through our laboratories and clinics at the National Institutes of Health to our vast network of supported research" (#9)

"Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. We are among the world's leading biotech companies, with multiple products on the market and a promising development pipeline" (#14). Such products include AIDS vaccines and drugs.

"Calimmune was founded in 2006 based on breakthrough gene modification and cell delivery technology developed in the labs of Nobel Laureate David Baltimore, Ph.D. (California Institute of Technology), Irvin Chen, Ph.D. (University of California, Los Angeles) and Inder M. Verma, Ph.D. (Salk Institute for Biological Studies). Our team has since advanced an aggressive candidate pipeline for the treatment and potential eradication of HIV/AIDS" (#7).

"Bristol-Myers Squibb is focused on addressing the significant unmet medical needs of patients with chronic viral disease and related illnesses. We concentrate our efforts on hepatitis B and C, and HIV/AIDS, where we seek significant improvements in cure rates, survival and quality of life" (#15).

"The Stanford Clinical Virology Laboratory is widely recognized as a pioneer in HIV-1 genotyping and antiviral resistance testing. This testing has revolutionized thecare of HIV infected patients and significantly advanced HIV research" (#13).

"Researchers at UC Berkeley and the National Institutes of Health have instead focused on a fourth protein, Nef, that hijacks host proteins and is essential to HIV’s lethality. The researchers have captured a high-resolution snapshot of Nef bound with a main host protein, and discovered a portion of the host protein that will make a promising target for the next-generation of anti-HIV drugs" (#11).